It appears the FDA aren't convinced it works. The only published RCT says it doesn't. I think I see the problem.
' Remestemcel-L did not meet the primary endpoint of greater DCR in the intent-to-treat population (35% versus 30%; P = 0.42).'
Whats all the whining about?
- Forums
- ASX - By Stock
- MSB
- Over $2buck hit
MSB
mesoblast limited
Add to My Watchlist
5.26%
!
$2.40

Over $2buck hit, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.40 |
Change
0.120(5.26%) |
Mkt cap ! $3.084B |
Open | High | Low | Value | Volume |
$2.31 | $2.43 | $2.30 | $12.67M | 5.346M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 8256 | $2.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.41 | 53153 | 40 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 2976 | 2.400 |
29 | 115621 | 2.390 |
19 | 129405 | 2.380 |
14 | 189142 | 2.370 |
13 | 83646 | 2.360 |
Price($) | Vol. | No. |
---|---|---|
2.410 | 53555 | 41 |
2.420 | 80340 | 31 |
2.430 | 154414 | 18 |
2.440 | 66857 | 10 |
2.450 | 178721 | 19 |
Last trade - 15.10pm 23/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |